Oxford-AstraZeneca's COVID-19 vaccine is at least 70 percent effective in late-stage trial
Oxford University and drugmaker AstraZeneca announced Monday morning that their COVID-19 vaccine candidate had proved to be 70 percent effective in its Phase Three trial of 20,000 volunteers in Britain and Brazil. And Oxford Vaccine Group director Andrew Pollard told BBC Radio 4 Today that the vaccine appeared to be 90 percent effective when people were given a half-dose of the vaccine followed by a full dose.
"We are really pleased with these results," Pollard said. "What we have got is a vaccine that is able to protect against coronavirus disease and, importantly, there were no hospitalizations or severe cases in anyone who had the Oxford vaccine." Sarah Gilbert, the vaccine's architect, said "the announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by" the new coronavirus.
Britain has ordered 100 million doses of the Oxford vaccine, and if U.K. regulators approve it for emergency use, the country is ready to roll out an aggressive immunization program. Residents and staff of nursing homes are first on the list of those approved for vaccinations, followed by health care workers and people over 85, then consecutively lower age groups.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"After Pfizer and Modena both produced vaccines delivering 95 percent protection from COVID-19, a figure of 70 percent is relatively disappointing," BBC News reports. "However, anything above 50 percent would have been considered a triumph just a month ago. This vaccine can also be stored at fridge temperature, which means it can be distributed to every corner of the world, unlike the Pfizer/BioNTech and Moderna vaccines, which need to be stored at much colder temperatures."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
How is aid getting into Gaza right now?
Today's Big Question The international effort to provide Palestinians with essentials during wartime has become a Gordian knot of logistics
By Rafi Schwartz, The Week US Published
-
The lows of an unregulated high: Teens are using marijuana alternative delta-8
In the Spotlight More than 1 in 10 high school seniors have reported using the substance, which contains concentrated THC
By Justin Klawans, The Week US Published
-
Michigan shooter's dad guilty of manslaughter
speed read James Crumbley failed to prevent his son from killing four students at Oxford High School in 2021
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published
-
Immigration helped the US economy outpace peers
speed read The U.S. economy grew at an annualized rate of 3.2% last quarter
By Peter Weber, The Week US Published
-
4-day workweek gets boost from UK study
Speed Read Following a six-month trial, the majority of participating British companies are still using the truncated schedule
By Peter Weber, The Week US Published
-
US sues to block Kroger-Albertsons merger
Speed Read The Federal Trade Commission sued to block the $24.6 billion merger between the grocery giants
By Peter Weber, The Week US Published
-
Nvidia sees historic stock rise on AI chips success
Speed Read U.S. chipmaker Nvidia achieved the biggest one-day increase in value of any company in history
By Peter Weber, The Week US Published
-
New York may seize Trump's assets for $450M penalty
Speed Read The former president likely owes $600 million from two civil judgments in New York
By Peter Weber, The Week US Published
-
Capital One to buy Discover for $35B
Speed Read The deal, if cleared by regulators, would create the biggest credit card lender in the country
By Peter Weber, The Week US Published
-
Sports Illustrated publisher fires CEO after allegedly getting caught using AI-generated articles
Speed Read The CEO is one of several executives to be fired in the wake of the scandal
By Justin Klawans, The Week US Published